Andere Sprachen AegirBio AB

Aktien

A2P7ZC

SE0014401121

AEGIR

Markt geschlossen - Nasdaq Stockholm Andere Börsenplätze 17:16:15 29.04.2024			% 5 Tage	% 1. Jan.
0,495 ^SEK	-4,62 %		-6,25 %	-57,69 %

09.04.	AegirBio unterzeichnet eine bedingte Vereinbarung über ein Darlehen von 45 Millionen SEK mit Atlas	MT
09.04.	AegirBio-Vorsitzender will zurücktreten	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

AegirBio Unit Begins Arbitration Proceedings vs Salofa for Breach of Contract	19.04.
AegirBio AB's subsidiary initiates arbitration against Salofa Oy	18.04.
AegirBio Signs Conditional Agreement for SEK45 Million Loan With Atlas	09.04.
AegirBio Chairman to Resign	09.04.
AegirBio's chairman has announced his intention to leave the board of directors	09.04.
AegirBio AB Announces Intention of Anders Ingvarsson to Resign as Board Member and Chairman	09.04.
AegirBio enters into a conditional agreement on a MSEK 45 loan facility with Atlas Special Opportunities and an agreement to amend the outstanding convertible bonds, subject to EGM approval	09.04.
AegirBio AB Enters into Conditional Agreement on a SEK 45 Million Loan Facility with Atlas Special Opportunities, LLC	09.04.
AegirBio AB Reports Earnings Results for the Full Year Ended December 31, 2023	29.03.
AegirBio AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29.03.
Aegirbio Expands Oral Health Scientific Advisory Board with Professor Iain L.C. Chapple	27.02.
AegirBio AB Announces the Appointment of Iain L. C. Chapple to the Scientific Advisory Board	27.02.
Renowned Gastroenterologist, Dr. Adam S. Cheifetz, Joins AegirBio's Scientific Advisory Board	24.01.
AegirBio AB Appoints Adam S. Cheifetz as Scientific Advisory Board	24.01.
AegirBio AB: Atlas Special Opportunities, LLC calls for partial conversion of outstanding convertible bonds to a nominal amount of MSEK 5.00	20.12.
AegirBio AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	24.11.
AegirBio Receives Portion of National Institutes of Health Award	01.11.
AegirBio Shifts Business Focus to Diagnostics Initiative in US	01.11.
AegirBio AB Receives $239,547 award from the National Institutes of Health RADx Tech Program	01.11.
Aegirbio AB Receives Phase 1 Award from the National Institutes of Health Rapid Acceleration of Diagnostics (Radx®) Tech Program for an Accessibility Project for Multiplex Testing	01.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen AegirBio AB

Aktien

A2P7ZC

SE0014401121

AEGIR

Andere Sprachen

Filter